These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38314724)

  • 1. Everolimus exerts anticancer effects through inhibiting the interaction of matrix metalloproteinase-7 with syndecan-2 in colon cancer cells.
    Lee S; Jang B; Hwang J; Lee Y; Cho S; Yang H; Yun JH; Shin DH; Lee W; Oh ES
    Am J Physiol Cell Physiol; 2024 Apr; 326(4):C1067-C1079. PubMed ID: 38314724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Syndecan-2 cytoplasmic domain up-regulates matrix metalloproteinase-7 expression via the protein kinase Cγ-mediated FAK/ERK signaling pathway in colon cancer.
    Jang B; Jung H; Choi S; Lee YH; Lee ST; Oh ES
    J Biol Chem; 2017 Sep; 292(39):16321-16332. PubMed ID: 28821612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substituted Syndecan-2-Derived Mimetic Peptides Show Improved Antitumor Activity over the Parent Syndecan-2-Derived Peptide.
    Jang B; Kim A; Lee Y; Hwang J; Sung JY; Jang EJ; Kim YN; Yun JH; Han J; Song JJ; Lee W; Oh ES
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The matrix metalloproteinase-7 regulates the extracellular shedding of syndecan-2 from colon cancer cells.
    Choi S; Kim JY; Park JH; Lee ST; Han IO; Oh ES
    Biochem Biophys Res Commun; 2012 Jan; 417(4):1260-4. PubMed ID: 22227189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine 51 residue of the syndecan-2 extracellular domain is involved in the interaction with and activation of pro-matrix metalloproteinase-7.
    Jang B; Yun JH; Choi S; Park J; Shin DH; Lee ST; Lee W; Oh ES
    Sci Rep; 2019 Jul; 9(1):10625. PubMed ID: 31337828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Syndecan-2 functions as a docking receptor for pro-matrix metalloproteinase-7 in human colon cancer cells.
    Ryu HY; Lee J; Yang S; Park H; Choi S; Jung KC; Lee ST; Seong JK; Han IO; Oh ES
    J Biol Chem; 2009 Dec; 284(51):35692-701. PubMed ID: 19858218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-1α promotes extracellular shedding of syndecan-2 via induction of matrix metalloproteinase-7 expression.
    Kwon MJ; Hong E; Choi Y; Kang DH; Oh ES
    Biochem Biophys Res Commun; 2014 Apr; 446(2):487-92. PubMed ID: 24613844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Syndecan-2 enhances E-cadherin shedding and fibroblast-like morphological changes by inducing MMP-7 expression in colon cancer cells.
    Jang B; Jung H; Chung H; Moon BI; Oh ES
    Biochem Biophys Res Commun; 2016 Aug; 477(1):47-53. PubMed ID: 27270030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The extracellular domain of syndecan-2 regulates the interaction of HCT116 human colon carcinoma cells with fibronectin.
    Kwon MJ; Kim Y; Choi Y; Kim SH; Park S; Han I; Kang DH; Oh ES
    Biochem Biophys Res Commun; 2013 Feb; 431(3):415-20. PubMed ID: 23333331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration.
    Endo K; Takino T; Miyamori H; Kinsen H; Yoshizaki T; Furukawa M; Sato H
    J Biol Chem; 2003 Oct; 278(42):40764-70. PubMed ID: 12904296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological inhibition of mTORC1 but not mTORC2 protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism through Akt and autophagy induction.
    Kakiuchi Y; Yurube T; Kakutani K; Takada T; Ito M; Takeoka Y; Kanda Y; Miyazaki S; Kuroda R; Nishida K
    Osteoarthritis Cartilage; 2019 Jun; 27(6):965-976. PubMed ID: 30716534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation.
    He K; Zheng X; Li M; Zhang L; Yu J
    Oncogene; 2016 Jan; 35(2):148-57. PubMed ID: 25867072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex.
    Ebrahimi-Fakhari D; Agricola KD; Tudor C; Krueger D; Franz DN
    Pediatr Neurol; 2020 Apr; 105():59-61. PubMed ID: 31924480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The heparan sulfate proteoglycan syndecan-1 regulates colon cancer stem cell function via a focal adhesion kinase-Wnt signaling axis.
    Kumar Katakam S; Tria V; Sim WC; Yip GW; Molgora S; Karnavas T; Elghonaimy EA; Pelucchi P; Piscitelli E; Ibrahim SA; Zucchi I; Reinbold R; Greve B; Götte M
    FEBS J; 2021 Jan; 288(2):486-506. PubMed ID: 32367652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinase-7 induces homotypic tumor cell aggregation via proteolytic cleavage of the membrane-bound Kunitz-type inhibitor HAI-1.
    Ishikawa T; Kimura Y; Hirano H; Higashi S
    J Biol Chem; 2017 Dec; 292(50):20769-20784. PubMed ID: 29046355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells.
    Huang XB; Yang CM; Han QM; Ye XJ; Lei W; Qian WB
    Acta Pharmacol Sin; 2018 Dec; 39(12):1894-1901. PubMed ID: 30297804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
    Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Jeon JI; Lee KH; Kim JM
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769248
    [No Abstract]   [Full Text] [Related]  

  • 19. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Pathways Leading to Induction of Cell Death and Anti-Proliferative Properties by Tacrolimus and mTOR Inhibitors in Liver Cancer Cells.
    Navarro-Villarán E; de la Cruz-Ojeda P; Contreras L; González R; Negrete M; Rodríguez-Hernández MA; Marín-Gómez LM; Álamo-Martínez JM; Calvo A; Gómez-Bravo MA; de la Cruz J; Padillo J; Muntané J
    Cell Physiol Biochem; 2020 May; 54(3):457-473. PubMed ID: 32369692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.